SCHEMBL5136790

SCHEMBL5136790

CCCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(CCCC)Cc1cccc(OC)c1O

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.42
PTGS2 P35354 1/20 0.42
BCHE P06276 9/20 0.39
ACHE P22303 4/20 0.39
GAA P10253 3/20 0.38
TP53 P04637 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TSHR P16473 2/20 0.38
CNR2 P34972 1/20 0.38
ALDH1A1 P00352 1/20 0.38
PKM P14618 1/20 0.38
C5AR1 P21730 1/20 0.37
MAPT P10636 1/20 0.37
CASR P41180 1/20 0.37
TLR8 Q9NR97 1/20 0.37
LMNA P02545 1/20 0.37
MAPK1 P28482 1/20 0.37
MAOB P27338 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135036 0.92 KDM4E (0.38) BCHETP53TSHRALDH1A1C5AR1
SCHEMBL5135095 0.92 BCHE (0.47) BCHEACHEGAATP53SMN1; SMN2
SCHEMBL5136719 0.89 EGFR (0.43) TP53TSHRALDH1A1C5AR1MAPT
SCHEMBL5069962 0.89 BCHE (0.45) BCHEACHETSHRC5AR1CASR
SCHEMBL5074221 0.88 GAA (0.38) BCHEACHEGAATP53SMN1; SMN2
SCHEMBL5136469 0.88 TP53 (0.41) BCHEACHEGAATP53SMN1; SMN2
SCHEMBL5135959 0.88 HDAC1 (0.36) BCHEGAATSHRALDH1A1PKM
SCHEMBL5137330 0.87 BCHE (0.43) BCHEACHEC5AR1CASR
SCHEMBL5134803 0.87 BCHE (0.43) BCHEACHEC5AR1MAOB
SCHEMBL5135183 0.85 PDE4B (0.39) BCHEACHETSHRALDH1A1C5AR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed